Phase 2 N=10 An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Papulopustular Rosacea
Primary: Facial Erythema — 6.6; 6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Eltrombopag for Post Transplant Thrombocytopenia
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
Phase 2 N=74 A Phase I/II Trial of Stereotactic Body Radiation Therapy
Inoperable Stage I/II Non-small Cell Lung Cancer
Primary: Phase I Portion Only: Determine the Maximum Tolerated Dose of SBRT — 11 Gy x 5 fractions
Phase 2 N=193 Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults
Malaria Vaccine
Primary: Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination — 1; 0; 0; 1 Participants
Phase 2 N=1,198 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Dengue Fever · Dengue Hemorrhagic Fever · Dengue Virus
Primary: Percentage of All Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Injection With CYD Dengue Vaccine or Placebo — 53.9; 66.7; 1.0…
Phase 2 N=989 Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents
Tuberculosis
Primary: Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents. — 286; 1257; 272 number of AEs
Phase 2 N=6 Choroideremia Gene Therapy Clinical Trial
Choroideremia
Primary: Change in Best Corrected Visual Acuity From Baseline — 3.0 Letters
Phase 2 N=174 Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Neurotrophic Keratitis · Keratitis · Corneal Ulcer
Primary: Percentage of Patients Achieving Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer — 55; 58; 20; 45 percentage of subjects — p=<0.001
Phase 2 N=61 Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
Marijuana Dependence
Primary: Physiological Changes in Response to Cue-induced Craving. — 5.65 T value
Phase 2 N=300 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Percentage of Participants (Aged 2 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or…
Phase 2 N=10 Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
Aplastic Anemia
Primary: ORR at 6 Months: Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at Week…
Phase 2 N=75 Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis
Anemia
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — -3.25; 3.5; -2.75 g/L
Phase 2 N=123 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon Adenocarcinoma · Rectal Adenocarcinoma · Stage III Colorectal Cancer AJCC v7
Primary: Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 — 0.43; 0.26 proportion of patients — p=0.0434
Phase 2 N=91 To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Resistance During Sleep, Promoting Nasal Route Breathing and Reducing the Signs and Symptoms of Sleep Disordered Breathing in a Group of Chronic Nocturnal Nasal Congestion Sufferers Who Report Trouble With Their Sleep.
Sleep Disordered Breathing · Congestion, Nasal
Primary: Nasal Resistance in Sleeping State : Nasal Resistance Phase — 2.658; 2.202 Centimeter (cm) H2O/liter/sec — p=0.0147
Phase 2 N=116 Statin Therapy in Acute Influenza
Influenza
Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611